An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
BELLUS Health, a clinical-stage biopharmaceutical company, announced participation by CEO Roberto Bellini in two upcoming healthcare investor conferences. The conferences are the Jefferies London Healthcare Conference on November 18, 2021, and the Evercore ISI HealthCONx Virtual Conference on December 1, 2021. Webcasts will be available on the company's website. BELLUS Health focuses on developing treatments for refractory chronic cough (RCC) and related disorders. Currently, there are no effective therapies approved for RCC, which affects about 9 million patients in the U.S.
Positive
None.
Negative
None.
LAVAL, Quebec--(BUSINESS WIRE)--
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in fireside chats at two upcoming healthcare investor conferences.
Presentation Details:
Event: Jefferies London Healthcare Conference Date/Time: On-demand starting Thursday, November 18, 2021 at 8:00 a.m. GMT
Event: 4th Annual Evercore ISI HealthCONx Virtual Conference Date/Time: Wednesday, December 1, 2021 at 11:20 a.m. EST
Webcasts of the Jefferies and Evercore fireside chats may be accessed on the Events & Presentations page under the Investors & Media section of BELLUS Health's website at www.bellushealth.com. Following the events, archived webcasts will be available on the Company’s website.
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of RCC and chronic pruritus associated with AD.
RCC is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in the United States suffering from RCC. RCC is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for RCC and treatment options are limited.
Chronic pruritus associated with AD is an irritating sensation that leads to scratching and persists for longer than 6 weeks in AD patients. It is estimated that up to 10% of adults in the United States suffer from AD – almost all report symptoms of pruritus with over 50% of patients attributing chronic pruritus as their most burdensome symptom. Despite currently available treatments targeting AD, there continues to be a lack of options specifically targeting the burden of pruritus in patients with AD.
What is the schedule for BELLUS Health's upcoming investor conferences?
BELLUS Health will participate in the Jefferies London Healthcare Conference on November 18, 2021, and the Evercore ISI HealthCONx Virtual Conference on December 1, 2021.
Where can I access the webcasts for BELLUS Health's conferences?
Webcasts for both conferences can be accessed on the Events & Presentations page on BELLUS Health's website.
What is BELLUS Health's focus regarding chronic cough treatment?
BELLUS Health is developing novel therapeutics for refractory chronic cough (RCC) and related hypersensitization disorders.
How many patients in the U.S. are affected by refractory chronic cough?
Approximately 9 million patients in the U.S. suffer from refractory chronic cough.
What is the significance of the Evercore ISI HealthCONx Virtual Conference for BELLUS Health?
The Evercore ISI HealthCONx Virtual Conference provides BELLUS Health an opportunity to engage with healthcare investors and discuss its pipeline and strategies.
